2020, Vol. 2, Issue 2, Part C

Patients and methods: A prospective study conducted between June 2004 and December 2004, which included patients who were admitted to our resuscitation department and who had hemoglobin values ​​below 10 after delivery or cesarean section and after gynecological surgery g.dL^-1. Three 200 mg doses of iron sucrose. Were administered intravenously on consecutive days. Fifteen days after the last dose, patients were called for analytical control and side effects were recorded. Use the student "t" test to perform paired-sample analysis on the data.

Results: 257 obstetricians and 52 gynecologists received treatment, of which 156 and 33 patients were completed, respectively. After obstetric treatment, hemoglobin increased to 3.2 g.dL^-1, and in obstetric and gynecology patients it was 2.7 g.dL^-1. Both results are statistically significant, p <0.001, and the confidence interval is 95% (2.92-3.52 for obstetric cases and 2.22-3.07 for gynecological cases). Side effects were rare (13 obstetric patients and one gynecological patient) and the majority (12 of 14 women) had pain at the injection site.

Conclusion: Intravenous iron sucrose is safe and effective in the treatment of puerperal anemia and gynecological surgery. The low incidence of serious side effects and the rapid recovery of hemoglobin levels make it a safe and effective drug for the treatment of anemia.